IQVIA Holdings Inc. (NYSE:IQV – Get Free Report) was the target of a significant drop in short interest in December. As of December 15th, there was short interest totalling 2,810,000 shares, a drop of 9.6% from the November 30th total of 3,110,000 shares. Based on an average daily trading volume, of 1,520,000 shares, the days-to-cover ratio is currently 1.8 days. Currently, 1.6% of the shares of the stock are short sold.
Analysts Set New Price Targets
Several equities analysts have recently weighed in on the stock. The Goldman Sachs Group reduced their price objective on shares of IQVIA from $280.00 to $250.00 and set a “buy” rating for the company in a research report on Friday, November 1st. William Blair restated an “outperform” rating on shares of IQVIA in a research report on Wednesday, December 11th. JPMorgan Chase & Co. cut their price objective on IQVIA from $279.00 to $240.00 and set an “overweight” rating for the company in a research report on Tuesday, November 5th. Deutsche Bank Aktiengesellschaft decreased their target price on IQVIA from $270.00 to $265.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Finally, Truist Financial reduced their target price on IQVIA from $265.00 to $261.00 and set a “buy” rating for the company in a report on Thursday, December 12th. Four equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, IQVIA has an average rating of “Moderate Buy” and an average target price of $255.82.
Read Our Latest Research Report on IQV
IQVIA Stock Down 0.5 %
Institutional Investors Weigh In On IQVIA
Hedge funds and other institutional investors have recently made changes to their positions in the company. Canada Pension Plan Investment Board lifted its stake in shares of IQVIA by 6.6% in the 2nd quarter. Canada Pension Plan Investment Board now owns 3,403,488 shares of the medical research company’s stock valued at $719,634,000 after purchasing an additional 211,653 shares during the last quarter. Farallon Capital Management LLC lifted its position in shares of IQVIA by 3.1% in the second quarter. Farallon Capital Management LLC now owns 2,923,032 shares of the medical research company’s stock worth $618,046,000 after buying an additional 86,870 shares during the last quarter. FMR LLC boosted its stake in shares of IQVIA by 38.7% during the 3rd quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock worth $684,213,000 after acquiring an additional 804,963 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in shares of IQVIA by 46.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock valued at $437,378,000 after acquiring an additional 583,396 shares during the last quarter. Finally, Impax Asset Management Group plc raised its stake in shares of IQVIA by 9.7% in the 3rd quarter. Impax Asset Management Group plc now owns 1,793,010 shares of the medical research company’s stock valued at $423,885,000 after acquiring an additional 157,809 shares in the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.
About IQVIA
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Further Reading
- Five stocks we like better than IQVIA
- Basic Materials Stocks Investing
- Work and Play: Investing in the Rise of Bleisure Travel
- How to Use the MarketBeat Stock Screener
- Top Dividend Stocks to Buy Now as Bond Yields Could Lower
- Diversification Can Smooth Returns And Mitigate Portfolio Risk
- SAP: AI Tailwinds Accelerating Enterprise Cloud Business
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.